drugset
drugset / Trial / NCT02195167

Dasotraline SEP360-105 Pediatric PK/PD Study

NCT02195167 ↗

Phase 1 Completed 105 enrolled Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

Pediatric PK study of SEP-225289 (Dasotraline)

Timeline

Start
2014-07
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Dasotraline Small molecule 1 mg Oral
Subject Dasotraline Small molecule 2 mg Oral
Subject Dasotraline Small molecule 4 mg Oral
Subject Dasotraline Small molecule 8 mg Oral
Subject Dasotraline Small molecule 12 mg Oral
Subject Dasotraline Small molecule 16 mg Oral
Subject Dasotraline Small molecule 20 mg Oral
Subject Dasotraline Small molecule 24 mg Oral
Subject Dasotraline Small molecule 28 mg Oral
Subject Dasotraline Small molecule 32 mg Oral

Indications

attention deficit-hyperactivity disorder